

1. **Aberham, C., S. Weber, and W. Phares.** 1996. Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. *J Virol* **70**:3536-44.
2. **Ackerson, B., O. Rey, J. Canon, and P. Krogstad.** 1998. Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A. *J Virol* **72**:303-8.
3. **Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin.** 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. *J Virol* **59**:284-91.
4. **Aiken, C.** 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. *J Virol* **71**:5871-7.
5. **Asmal, M., J. Colgan, F. Naef, B. Yu, Y. Lee, M. Magnasco, and J. Luban.** 2003. Production of ribosome components in effector CD4⁺ T cells is accelerated by TCR stimulation and coordinated by ERK-MAPK. *Immunity* **19**:535-48.
6. **Baltimore, D.** 1970. RNA-dependent DNA polymerase in virions of RNA tumour viruses. *Nature* **226**:1209-11.
7. **Balzarini, J., E. De Clercq, and K. Uberla.** 1997. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. *J Acquir Immune Defic Syndr Hum Retrovirol* **15**:1-4.
8. **Bedinger, P., A. Moriarty, R. C. von Borstel, 2nd, N. J. Donovan, K. S. Steimer, and D. R. Littman.** 1988. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. *Nature* **334**:162-5.
9. **Benit, L., N. De Parseval, J. F. Casella, I. Callebaut, A. Cordonnier, and T. Heidmann.** 1997. Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene. *J Virol* **71**:5652-7.
10. **Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg.** 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. *Nature* **345**:622-5.
11. **Berthoux, L., S. Sebastian, E. Sokolskaja, and J. Luban.** 2005. Cyclophilin A is required for TRIM5 α -mediated resistance to HIV-1 in Old World monkey cells. *Proc Natl Acad Sci U S A* **102**:14849-53.
12. **Berthoux, L., S. Sebastian, E. Sokolskaja, and J. Luban.** 2004. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. *J Virol* **78**:11739-50.
13. **Berthoux, L., G. J. Towers, C. Gurer, P. Salomoni, P. P. Pandolfi, and J. Luban.** 2003. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. *J Virol* **77**:3167-80.

14. **Besnier, C., Y. Takeuchi, and G. Towers.** 2002. Restriction of lentivirus in monkeys. *Proc Natl Acad Sci U S A* **99**:11920-5.
15. **Besnier, C., L. Ylinen, B. Strange, A. Lister, Y. Takeuchi, S. P. Goff, and G. J. Towers.** 2003. Characterization of murine leukemia virus restriction in mammals. *J Virol* **77**:13403-6.
16. **Best, S., P. Le Tissier, G. Towers, and J. P. Stoye.** 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. *Nature* **382**:826-9.
17. **Boone, L. R., C. L. Innes, and C. K. Heitman.** 1990. Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. *J Virol* **64**:3376-81.
18. **Bosco, D. A., E. Z. Eisenmesser, S. Pochapsky, W. I. Sundquist, and D. Kern.** 2002. Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. *Proc Natl Acad Sci U S A* **99**:5247-52.
19. **Braaten, D., C. Aberham, E. K. Franke, L. Yin, W. Phares, and J. Luban.** 1996. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. *J Virol* **70**:5170-6.
20. **Braaten, D., H. Ansari, and J. Luban.** 1997. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. *J Virol* **71**:2107-13.
21. **Braaten, D., E. K. Franke, and J. Luban.** 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. *J Virol* **70**:3551-60.
22. **Braaten, D., E. K. Franke, and J. Luban.** 1996. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. *J Virol* **70**:4220-7.
23. **Braaten, D., and J. Luban.** 2001. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. *Embo J* **20**:1300-9.
24. **Bristow, R., J. Byrne, J. Squirell, H. Trencher, T. Carter, B. Rodgers, E. Saman, and J. b. Duncan.** 1999. Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24. *J Acquir Immune Defic Syndr Hum Retrovirol* **20**:334-6.
25. **Brummelkamp, T. R., R. Bernards, and R. Agami.** 2002. A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**:550-3.
26. **Buechen-Osmond, C.** 2005. Universal Virus Database of the International Committee on Taxonomy of Viruses. <http://www.ncbi.nlm.nih.gov/ICTVdb/index.htm>.
27. **Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski.** 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* **85**:1135-48.
28. **Coffin, J. M.** 1992. Genetic diversity and evolution of retroviruses. *Curr Top Microbiol Immunol* **176**:143-64.
29. **Coffin, J. M., Hughes, S.H. and Varmus, H.** 1997. *Retroviruses*. Cold Spring Harbor Laboratory Press, Plainview, N.Y.

30. **Colgan, J., H. E. Yuan, E. K. Franke, and J. Luban.** 1996. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. *J Virol* **70**:4299-310.
31. **Cowan, S., T. Hatzioannou, T. Cunningham, M. A. Muesing, H. G. Gottlinger, and P. D. Bieniasz.** 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. *Proc Natl Acad Sci U S A* **99**:11914-9.
32. **Dalglish, A. G., P. C. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss.** 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature* **312**:763-7.
33. **Decleve, A., O. Niwa, E. Gelmann, and H. S. Kaplan.** 1975. Replication kinetics of N- and B-tropic murine leukemia viruses on permissive and nonpermissive cells in vitro. *Virology* **65**:320-32.
34. **Demaison, C., K. Parsley, G. Brouns, M. Scherr, K. Battmer, C. Kinnon, M. Grez, and A. J. Thrasher.** 2002. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. *Hum Gene Ther* **13**:803-13.
35. **Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau.** 1996. Identification of a major co-receptor for primary isolates of HIV-1. *Nature* **381**:661-6.
36. **Dorfman, T., and H. G. Gottlinger.** 1996. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. *J Virol* **70**:5751-7.
37. **Emi, N., T. Friedmann, and J. K. Yee.** 1991. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. *J Virol* **65**:1202-7.
38. **Endres, M. J., P. R. Clapham, M. Marsh, M. Ahuja, J. D. Turner, A. McKnight, J. F. Thomas, B. Stoebenau-Haggarty, S. Choe, P. J. Vance, T. N. Wells, C. A. Power, S. S. Sutterwala, R. W. Doms, N. R. Landau, and J. A. Hoxie.** 1996. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. *Cell* **87**:745-56.
39. **Fehr, T., J. Kallen, L. Oberer, J. J. Sanglier, and W. Schilling.** 1999. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from *Streptomyces* sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. *J Antibiot (Tokyo)* **52**:474-9.
40. **Feng, Q., J. V. Moran, H. H. Kazazian, Jr., and J. D. Boeke.** 1996. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. *Cell* **87**:905-16.
41. **Fischer, G., H. Bang, and C. Mech.** 1984. [Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides]. *Biomed Biochim Acta* **43**:1101-11.
42. **Fischer, G., T. Tradler, and T. Zarnt.** 1998. The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. *FEBS Lett* **426**:17-20.

43. **Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj.** 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. *Cell* **90**:1051-60.
44. **Franke, E. K., B. X. Chen, I. Tatsis, A. Diamanduros, B. F. Erlanger, and J. Luban.** 1995. Cyclophilin binding to the human immunodeficiency virus type 1 Gag polyprotein is mimicked by an anti-cyclosporine antibody. *J Virol* **69**:5821-3.
45. **Franke, E. K., and J. Luban.** 1996. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. *Virology* **222**:279-82.
46. **Franke, E. K., H. E. Yuan, and J. Luban.** 1994. Specific incorporation of cyclophilin A into HIV-1 virions. *Nature* **372**:359-62.
47. **Friedman, J., and I. Weissman.** 1991. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. *Cell* **66**:799-806.
48. **Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill.** 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. *Cell* **87**:1285-94.
49. **Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist.** 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. *Cell* **107**:55-65.
50. **Gitti, R. K., B. M. Lee, J. Walker, M. F. Summers, S. Yoo, and W. I. Sundquist.** 1996. Structure of the amino-terminal core domain of the HIV-1 capsid protein. *Science* **273**:231-5.
51. **Grattinger, M., H. Hohenberg, D. Thomas, T. Wilk, B. Muller, and H. G. Krausslich.** 1999. In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A. *Virology* **257**:247-60.
52. **Handschumacher, R. E., M. W. Harding, J. Rice, R. J. Drugge, and D. W. Speicher.** 1984. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. *Science* **226**:544-7.
53. **Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim.** 2003. DNA deamination mediates innate immunity to retroviral infection. *Cell* **113**:803-9.
54. **Hatzioannou, T., S. Cowan, S. P. Goff, P. D. Bieniasz, and G. J. Towers.** 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. *Embo J* **22**:385-94.
55. **Hatzioannou, T., D. Perez-Caballero, S. Cowan, and P. D. Bieniasz.** 2005. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. *J Virol* **79**:176-83.
56. **Hatzioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz.** 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. *Proc Natl Acad Sci U S A* **101**:10774-9.
57. **He, J., Y. Chen, M. Farzan, H. Choe, A. Ohagen, S. Gartner, J. Busciglio, X. Yang, W. Hofmann, W. Newman, C. R. Mackay, J. Sodroski, and D. Gabuzda.** 1997. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature* **385**:645-9.

58. **Himathongkham, S., and P. A. Luciw.** 1996. Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. *Virology* **219**:485-8.
59. **Hofmann, W., D. Schubert, J. LaBonte, L. Munson, S. Gibson, J. Scammell, P. Ferrigno, and J. Sodroski.** 1999. Species-specific, postentry barriers to primate immunodeficiency virus infection. *J Virol* **73**:10020-8.
60. **Ivery, M. T.** 2000. Immunophilins: switched on protein binding domains? *Med Res Rev* **20**:452-84.
61. **Jolicoeur, P., and D. Baltimore.** 1976. Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. *Proc Natl Acad Sci U S A* **73**:2236-40.
62. **Kasinrerk, W., N. Tokrasinwit, and P. Phunpae.** 1999. CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. *Immunology* **96**:184-92.
63. **Kawakami, K., C. Scheidereit, and R. G. Roeder.** 1988. Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. *Proc Natl Acad Sci U S A* **85**:4700-4.
64. **Keckesova, Z., L. M. Ylinen, and G. J. Towers.** 2004. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. *Proc Natl Acad Sci U S A* **101**:10780-5.
65. **Kern, D., T. Drakenberg, M. Wikstrom, S. Forsen, H. Bang, and G. Fischer.** 1993. The cis/trans interconversion of the calcium regulating hormone calcitonin is catalyzed by cyclophilin. *FEBS Lett* **323**:198-202.
66. **Klatzmann, D., E. Champagne, S. Chamaret, J. Gruet, D. Guetard, T. Hercend, J. C. Gluckman, and L. Montagnier.** 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature* **312**:767-8.
67. **Kong, L. B., D. An, B. Ackerson, J. Canon, O. Rey, I. S. Chen, P. Krogstad, and P. L. Stewart.** 1998. Cryoelectron microscopic examination of human immunodeficiency virus type 1 virions with mutations in the cyclophilin A binding loop. *J Virol* **72**:4403-7.
68. **Kootstra, N. A., C. Munk, N. Tonnu, N. R. Landau, and I. M. Verma.** 2003. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. *Proc Natl Acad Sci U S A* **100**:1298-303.
69. **Korber, B., M. Muldoon, J. Theiler, F. Gao, R. Gupta, A. Lapedes, B. H. Hahn, S. Wolinsky, and T. Bhattacharya.** 2000. Timing the ancestor of the HIV-1 pandemic strains. *Science* **288**:1789-96.
70. **Kozak, C. A., and A. Chakraborti.** 1996. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. *Virology* **225**:300-5.
71. **Lang, K., F. X. Schmid, and G. Fischer.** 1987. Catalysis of protein folding by prolyl isomerase. *Nature* **329**:268-70.
72. **Li, J., C. I. Lord, W. Haseltine, N. L. Letvin, and J. Sodroski.** 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. *J Acquir Immune Defic Syndr* **5**:639-46.
73. **Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch.** 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. *Nature* **407**:409-13.

74. **Lilly, F.** 1967. Susceptibility to two strains of Friend leukemia virus in mice. *Science* **155**:461-2.
75. **Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber.** 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* **66**:807-15.
76. **Luban, J.** 1996. Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. *Cell* **87**:1157-9.
77. **Luban, J., K. L. Bossolt, E. K. Franke, G. V. Kalpana, and S. P. Goff.** 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. *Cell* **73**:1067-78.
78. **Matlin, K. S., H. Reggio, A. Helenius, and K. Simons.** 1982. Pathway of vesicular stomatitis virus entry leading to infection. *J Mol Biol* **156**:609-31.
79. **Mortuza, G. B., L. F. Haire, A. Stevens, S. J. Smerdon, J. P. Stoye, and I. A. Taylor.** 2004. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. *Nature* **431**:481-5.
80. **Munk, C., S. M. Brandt, G. Lucero, and N. R. Landau.** 2002. A dominant block to HIV-1 replication at reverse transcription in simian cells. *Proc Natl Acad Sci U S A* **99**:13843-8.
81. **Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma.** 1996. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. *J Virol* **70**:5701-5.
82. **Nisole, S., C. Lynch, J. P. Stoye, and M. W. Yap.** 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. *Proc Natl Acad Sci U S A* **101**:13324-8.
83. **Odaka, T., H. Ikeda, H. Yoshikura, K. Moriwaki, and S. Suzuki.** 1981. Fv-4: gene controlling resistance to NB-tropic Friend murine leukemia virus. Distribution in wild mice, introduction into genetic background of BALB/c mice, and mapping of chromosomes. *J Natl Cancer Inst* **67**:1123-7.
84. **Oroszlan, S., and R. B. Luftig.** 1990. Retroviral proteinases. *Curr Top Microbiol Immunol* **157**:153-85.
85. **Ott, D. E., L. V. Coren, D. G. Johnson, R. C. Sowder, 2nd, L. O. Arthur, and L. E. Henderson.** 1995. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. *AIDS Res Hum Retroviruses* **11**:1003-6.
86. **Owens, C. M., B. Song, M. J. Perron, P. C. Yang, M. Stremlau, and J. Sodroski.** 2004. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. *J Virol* **78**:5423-37.
87. **Owens, C. M., P. C. Yang, H. Gottlinger, and J. Sodroski.** 2003. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. *J Virol* **77**:726-31.
88. **Panganiban, A. T., and H. M. Temin.** 1984. The retrovirus pol gene encodes a product required for DNA integration: identification of a retrovirus int locus. *Proc Natl Acad Sci U S A* **81**:7885-9.

89. **Passerini, L. D., Z. Keckesova, and G. J. Towers.** 2006. Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription. *J Virol* **80**:2100-5.
90. **Perez-Caballero, D., T. Hatzioannou, A. Yang, S. Cowan, and P. D. Bieniasz.** 2005. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. *J Virol* **79**:8969-78.
91. **Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski.** 2004. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. *Proc Natl Acad Sci U S A* **101**:11827-32.
92. **Pincus, T., J. W. Hartley, and W. P. Rowe.** 1975. A major genetic locus affecting resistance to infection with murine leukemia viruses. IV. Dose-response relationships in Fv-1-sensitive and resistant cell cultures. *Virology* **65**:333-42.
93. **Pryciak, P. M., and H. E. Varmus.** 1992. Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro. *J Virol* **66**:5959-66.
94. **Pushkarsky, T., V. Yurchenko, C. Vanpouille, B. Brichacek, I. Vaisman, S. Hatakeyama, K. I. Nakayama, B. Sherry, and M. I. Bukrinsky.** 2005. Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. *J Biol Chem* **280**:27866-71.
95. **Reymond, A., G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio.** 2001. The tripartite motif family identifies cell compartments. *Embo J* **20**:2140-51.
96. **Ribeiro, I. P., A. N. Menezes, M. A. Moreira, C. R. Bonvicino, H. N. Seuanez, and M. A. Soares.** 2005. Evolution of cyclophilin A and TRIMCyp retrotransposition in New World primates. *J Virol* **79**:14998-5003.
97. **Rosenwirth, B., A. Billich, R. Datema, P. Donatsch, F. Hammerschmid, R. Harrison, P. Hiestand, H. Jaksche, P. Mayer, P. Peichl, and et al.** 1994. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. *Antimicrob Agents Chemother* **38**:1763-72.
98. **Sakuragi, S., R. Shibata, R. Mukai, T. Komatsu, M. Fukasawa, H. Sakai, J. Sakuragi, M. Kawamura, K. Ibuki, M. Hayami, and et al.** 1992. Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. *J Gen Virol* **73 (Pt 11)**:2983-7.
99. **Salemi, M., K. Strimmer, W. W. Hall, M. Duffy, E. Delaporte, S. Mboup, M. Peeters, and A. M. Vandamme.** 2001. Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. *Faseb J* **15**:276-8.
100. **Sanglier, J. J., V. Quesniaux, T. Fehr, H. Hofmann, M. Mahnke, K. Memmert, W. Schuler, G. Zenke, L. Gschwind, C. Maurer, and W. Schilling.** 1999. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from *Streptomyces* sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. *J Antibiot (Tokyo)* **52**:466-73.
101. **Sawyer, S. L., L. I. Wu, M. Emerman, and H. S. Malik.** 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. *Proc Natl Acad Sci U S A* **102**:2832-7.

102. **Sayah, D. M., and J. Luban.** 2004. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. *J Virol* **78**:12066-70.
103. **Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban.** 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. *Nature* **430**:569-73.
104. **Sebastian, S., and J. Luban.** 2005. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. *Retrovirology* **2**:40.
105. **Sharp, P. M., G. M. Shaw, and B. H. Hahn.** 2005. Simian immunodeficiency virus infection of chimpanzees. *J Virol* **79**:3891-902.
106. **Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim.** 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* **418**:646-50.
107. **Shibata, R., M. Kawamura, H. Sakai, M. Hayami, A. Ishimoto, and A. Adachi.** 1991. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. *J Virol* **65**:3514-20.
108. **Shibata, R., H. Sakai, M. Kawamura, K. Tokunaga, and A. Adachi.** 1995. Early replication block of human immunodeficiency virus type 1 in monkey cells. *J Gen Virol* **76 (Pt 11)**:2723-30.
109. **Sokolskaja, E., D. M. Sayah, and J. Luban.** 2004. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. *J Virol* **78**:12800-8.
110. **Song, B., B. Gold, C. O'Huigin, H. Javanbakht, X. Li, M. Stremlau, C. Winkler, M. Dean, and J. Sodroski.** 2005. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. *J Virol* **79**:6111-21.
111. **Song, B., H. Javanbakht, M. Perron, D. H. Park, M. Stremlau, and J. Sodroski.** 2005. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. *J Virol* **79**:3930-7.
112. **Stein, B. S., S. D. Gowda, J. D. Lifson, R. C. Penhallow, K. G. Bensch, and E. G. Engleman.** 1987. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. *Cell* **49**:659-68.
113. **Streblov, D. N., M. Kitabwalla, M. Malkovsky, and C. D. Pauza.** 1998. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. *Virology* **245**:197-202.
114. **Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski.** 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. *Nature* **427**:848-53.
115. **Stremlau, M., M. Perron, S. Welikala, and J. Sodroski.** 2005. Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5{alpha} Determines the Potency of Human Immunodeficiency Virus Restriction. *J Virol* **79**:3139-45.
116. **Suzuki, S.** 1975. FV-4: a new gene affecting the splenomegaly induction by Friend leukemia virus. *Jpn J Exp Med* **45**:473-8.
117. **Takahashi, N., T. Hayano, and M. Suzuki.** 1989. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. *Nature* **337**:473-5.

118. **Taylor, J. M.** 1977. An analysis of the role of tRNA species as primers for the transcription into DNA of RNA tumor virus genomes. *Biochim Biophys Acta* **473**:57-71.
119. **Temin, H. M., and S. Mizutani.** 1970. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. *Nature* **226**:1211-3.
120. **Thali, M., A. Bukovsky, E. Kondo, B. Rosenwirth, C. T. Walsh, J. Sodroski, and H. G. Gottlinger.** 1994. Functional association of cyclophilin A with HIV-1 virions. *Nature* **372**:363-5.
121. **Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos.** 2000. A conserved mechanism of retrovirus restriction in mammals. *Proc Natl Acad Sci U S A* **97**:12295-9.
122. **Towers, G., M. Collins, and Y. Takeuchi.** 2002. Abrogation of Ref1 retrovirus restriction in human cells. *J Virol* **76**:2548-50.
123. **Towers, G. J., T. Hatziioannou, S. Cowan, S. P. Goff, J. Luban, and P. D. Bieniasz.** 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. *Nat Med* **9**:1138-43.
124. **Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore.** 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. *Immunity* **11**:281-8.
125. **Vigna, E., and L. Naldini.** 2000. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. *J Gene Med* **2**:308-16.
126. **Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones.** 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* **92**:451-62.
127. **Wieggers, K., and H. G. Krausslich.** 2002. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. *Virology* **294**:289-95.
128. **Wieggers, K., G. Rutter, U. Schubert, M. Grattinger, and H. G. Krausslich.** 1999. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. *Virology* **257**:261-74.
129. **Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye.** 2004. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. *Proc Natl Acad Sci U S A* **101**:10786-91.
130. **Yap, M. W., S. Nisole, and J. P. Stoye.** 2005. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. *Curr Biol* **15**:73-8.
131. **Yee, J. K., T. Friedmann, and J. C. Burns.** 1994. Generation of high-titer pseudotyped retroviral vectors with very broad host range. *Methods Cell Biol* **43 Pt A**:99-112.
132. **Yee, J. K., A. Miyanojara, P. LaPorte, K. Bouic, J. C. Burns, and T. Friedmann.** 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. *Proc Natl Acad Sci U S A* **91**:9564-8.

133. **Yin, L., D. Braaten, and J. Luban.** 1998. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. *J Virol* **72**:6430-6.
134. **Yoo, S., D. G. Myszka, C. Yeh, M. McMurray, C. P. Hill, and W. I. Sundquist.** 1997. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. *J Mol Biol* **269**:780-95.
135. **Zenke, G., U. Strittmatter, S. Fuchs, V. F. Quesniaux, V. Brinkmann, W. Schuler, M. Zurini, A. Enz, A. Billich, J. J. Sanglier, and T. Fehr.** 2001. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. *J Immunol* **166**:7165-71.
136. **Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono.** 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J Virol* **72**:9873-80.